A Phase 3 interventional study of Amlodipine and Olmesartan medoxomil in Hypertension, sponsored by Novartis. Completed at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-04.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 75th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 44th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 257 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 122nd largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2007, is one of 108 in phase 3, and was the 124th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of valsartan and amlodipine in fixed dose combination in adults with moderate, inadequately controlled hypertension. There was an optional study extension for eligible patients who wanted to participate that contains the triple therapy (ie, hydrochlorothiazide+ amlodipine/valsartan).
Title of study extension: An open-label, multicenter extension to evaluate the efficacy and tolerability of a 4 week therapy with hydrochlorothiazide 12.5 mg plus amlodipine 10 mg/valsartan 160 mg in hypertensive patients not adequately responding to a 4 week therapy each with the combinations of olmesartan 20 mg plus amlodipine 10 mg followed by amlodipine 10 mg/valsartan 160 mg
Inclusion Criteria for Core study:
Inclusion Criteria for Extension:
Exclusion Criteria for Core study:
Exclusion Criteria for Extension:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.
Drug: Amlodipine · Drug: Olmesartan medoxomil · Drug: Amlodipine+valsartan · Drug: Hydrochlorothiazide
Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
Drug pages: Amlodipine · Valsartan
Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
Also known as: Exforge
Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
Also known as: Sandoz
Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Change in Sitting Pulse Pressure During the Core Phase of the Study
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Change in Sitting Pulse Rate During the Core Phase of the Study
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.
Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
Normalized Blood Pressure was defined as a msSBP \< 140 mmHg and/or a msDBP \< 90 mmHg.
Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
Blood pressure response was defined as msSBP \< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 (Week 8) compared to Baseline in Phase 2 (week 4) or a msDBP \< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.
Time frame: Baseline of Phase 2 (Week 4) to end of Phase 2 (Week 8)
Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
Change in Sitting Pulse Pressure During the Extension Phase of the Study
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
Change in Sitting Pulse Rate During the Extension Phase of the Study
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.
Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (week 12)
Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study
Normalized Blood Pressure was defined as a msSBP \< 140 mmHg and/or a msDBP \< 90 mmHg.
Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study
Blood pressure response was defined as msSBP \< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 3 compared to Baseline in Phase 3 or a msDBP \< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 3 compared to Baseline in Phase 3.
Time frame: Baseline of Phase 3 (Week 8) to end of Phase 3 (Week 12)
| Milestone | Amlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ |
|---|---|
| Started | 257 |
| Completed | 251 |
| Not completed | 6 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Administrative problems | 1 |
| Milestone | Amlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ |
|---|---|
| Started | 176 |
| Completed | 173 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lost to follow-up | 1 |
| Milestone | Amlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ |
|---|---|
| Started | 91 |
| Completed | 91 |
| Not completed | 0 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
| mmHg | Amlodipine+Valsartan - Phase 2 |
|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study | -9.13 ± 1.97 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
| mmHg | Amlodipine+Valsartan - Phase 2 |
|---|---|
| Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study | -7.87 ± 9.48 |
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
| mmHg | Amlodipine+Valsartan - Phase 2 |
|---|---|
| Change in Sitting Pulse Pressure During the Core Phase of the Study | 1.26 ± 9.64 |
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.
| BPM (beats per minute) | Amlodipine+Valsartan - Phase 2 |
|---|---|
| Change in Sitting Pulse Rate During the Core Phase of the Study | -1.93 (-3.06 to -0.79) |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
| mmHg | Amlodipine+Valsartan+HCTZ - Phase 3 |
|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study | -5.22 (-6.76 to -3.68) |
Normalized Blood Pressure was defined as a msSBP \< 140 mmHg and/or a msDBP \< 90 mmHg.
| Percentage of participants | Amlodipine+Valsartan - Phase 2 |
|---|---|
| msSBP < 140 mmHg | 44.6 |
| msDBP < 90 mmHg | 72.6 |
Blood pressure response was defined as msSBP \< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 (Week 8) compared to Baseline in Phase 2 (week 4) or a msDBP \< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.
| Percentage of participants | Amlodipine+Valsartan - Phase 2 |
|---|---|
| msSBP response | 47.4 |
| msDBP response | 73.1 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
| mmHg | Amlodipine+Valsartan+HCTZ - Phase 3 |
|---|---|
| Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study | -10.84 (-12.94 to -8.75) |
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.
| mmHg | Amlodipine+Valsartan+HCTZ - Phase 3 |
|---|---|
| Change in Sitting Pulse Pressure During the Extension Phase of the Study | -5.62 (-7.74 to -3.50) |
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.
| BPM (beats per minute) | Amlodipine+Valsartan+HCTZ - Phase 3 |
|---|---|
| Change in Sitting Pulse Rate During the Extension Phase of the Study | 0.09 (-1.36 to 1.54) |
Normalized Blood Pressure was defined as a msSBP \< 140 mmHg and/or a msDBP \< 90 mmHg.
| Percentage of participants | Amlodipine+Valsartan+HCTZ - Phase 3 |
|---|---|
| msSBP < 140 mmHg | 59.3 |
| msDBP < 90 mmHg | 83.5 |
Blood pressure response was defined as msSBP \< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 3 compared to Baseline in Phase 3 or a msDBP \< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 3 compared to Baseline in Phase 3.
| Percentage of participants | Amlodipine+Valsartan+HCTZ - Phase 3 |
|---|---|
| msSBP response | 61.5 |
| msDBP response | 83.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 - Amlodipine+Olmesartan | — | 1/257 (0.4%) | 0/257 (0%) |
| Phase 2 - Amlodipine+Valsartan | — | 0/176 (0%) | 0/176 (0%) |
| Phase 3 - Amlodipine+Valsartan+HCTZ | — | 0/91 (0%) | 0/91 (0%) |
| Event | Phase 1 - Amlodipine+Olmesartan | Phase 2 - Amlodipine+Valsartan | Phase 3 - Amlodipine+Valsartan+HCTZ |
|---|---|---|---|
| SUDDEN HEARING LOSSEar and labyrinth disorders | 1/257 | 0/176 | 0/91 |
| Age, Continuous(years) | Amlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ |
|---|---|
| Phase 1 - Amlodipine+olmesartan | 58.8 ± 12.38 |
| Phase 2 - Amlodipine+valsartan | 59.8 ± 11.84 |
| Phase 3 - Amlodipine+valsartan+HCTZ | 60.9 ± 10.98 |
| Sex/Gender, Customized(participants) | Amlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ |
|---|---|
| Phase 1 - Amlodipine+olmesartan - Female | 112 |
| Phase 1 - Amlodipine+olmesartan - Male | 145 |
| Phase 2 - Amlodipine+valsartan - Female | 76 |
| Phase 2 - Amlodipine+valsartan - Male | 100 |
| Phase 3 - Amlodipine+valsartan+HCTZ - Female | 32 |
| Phase 3 - Amlodipine+valsartan+HCTZ - Male | 59 |
The record gives a start of Jul 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amlodipine · Valsartan